The Neurodevelopmental and Behavioral Phenotyping Service conducts over 200 neurodevelopmental assessments yearly, collecting and analyzying data from a variety of rare genetic disorders associated with Intellectual Disability and Autism Spectrum Disorder. Much of the data analyzed has been collected through a protocol that includes behavioral assessments (NCT00271622) and a collaborative protocol that includes assessment of specific rare genetic conditions (NCT02461420). In addition, we participate in several other multi-site studies that are conducting behavioral phenotyping of conditions that have yet to have their natural histories fully explored, including Phelan-McDermid Syndrome, Williams Syndrome, Moebius Syndrome, propionic acidemia, creatine transport deficiency, Smith-Lemli-Opitz Syndrome, congenital disorders of glycosylation and other diagnosed and undiagnosed conditions that affect neurodevelopment early in life. These characterization studies are necessary for understanding the breadth and depth of syndromes that cause lifelong impairments, based on developmental delays that often lead to Intellectual Disability and Autism Spectrum Disorder (ASD). Related to these goals, we seek to take advantage of gains made in identification of genetic abnormalities in those already diagnosed with ASD or Intellectual Disability, by exploring whether genotypic differences may be reflected in behavioral phenotype differences in cohorts of children diagnosed with these conditions. As such, we continue to explore data on ASD and at-risk populations collected through the NIMH intramural research program, including data from neuroimaging and sleep studies, and we have engaged in collaborative efforts to analyze genotype-phenotype data from large scale ASD collections and populations of children with ASD identified with specific genetic abnormalities. These analyses allow us to refine our understanding of when and how symptoms of neurodevelopmental disorders present if genetic etiologies are identified. We are specifically focused on the rates and types of Intellectual Disability and ASD profiles within rare genetic conditions, given the implications of these diagnoses on lifelong disability and the need for potential treatment targets and appropriate outcome measures. Our collection of data using standardized autism diagnostic instruments (e.g. the Autism Diagnostic Interview-Revised and the Autism Diagnostic Observation Schedule) and traditional measures of intellectual functioning and adaptive behavior allows us to conduct analyses on how use of these measures function over time, and on how measurements differs within specific genetic disorders, to gain an understanding of how ASD and neurocognitive profiles may present differently based on specific etiology. Given that the field is moving towards such genetics-first approaches, we also use data from our unique study populations to explore the limitations of our current measures and terminology for fully characterizing individuals who are minimally verbal or severely intellectually impaired. This group of children are particularly important for inclusion in potential treatment trials of rare genetic conditions, but for which few tools have been developed with adequate representation in standardization samples. We also plan to use such data to improve upon existing measures, and collaborate with others to develop new tools. Our goal here is to participate in the creation of tools that capture the full range of social-communication development, including the ability to capture profiles of those with early onset of neurologic conditions. We seek to create measures that capture growth and differences that may be important for recognizing change based on treatment as well as loss of skills that often accompanies both neurodevelopmental and neurodegenerative conditions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICMH002961-02
Application #
9790858
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
U.S. National Institute of Mental Health
Department
Type
DUNS #
City
State
Country
Zip Code
Khan, Omar I; Zhou, Xiangping; Leon, Jill et al. (2018) Prospective longitudinal overnight video-EEG evaluation in Phelan-McDermid Syndrome. Epilepsy Behav 80:312-320
Farmer, Cristan A; Chilakamarri, Priyanka; Thurm, Audrey E et al. (2018) Spindle activity in young children with autism, developmental delay, or typical development. Neurology 91:e112-e122
Mitz, Andrew R; Philyaw, Travis J; Boccuto, Luigi et al. (2018) Identification of 22q13 genes most likely to contribute to Phelan McDermid syndrome. Eur J Hum Genet 26:293-302
Thurm, Audrey; Powell, Elizabeth M; Neul, Jeffrey L et al. (2018) Loss of skills and onset patterns in neurodevelopmental disorders: Understanding the neurobiological mechanisms. Autism Res 11:212-222
Henry, Laura; Farmer, Cristan; Manwaring, Stacy S et al. (2018) Trajectories of cognitive development in toddlers with language delays. Res Dev Disabil 81:65-72
Farmer, Cristan; Swineford, Lauren; Swedo, Susan E et al. (2018) Classifying and characterizing the development of adaptive behavior in a naturalistic longitudinal study of young children with autism. J Neurodev Disord 10:1
Weiss, Karin; Kruszka, Paul; Guillen Sacoto, Maria J et al. (2017) In-depth investigations of adolescents and adults with holoprosencephaly identify unique characteristics. Genet Med :
Bishop, Somer L; Farmer, Cristan; Bal, Vanessa et al. (2017) Identification of Developmental and Behavioral Markers Associated With Genetic Abnormalities in Autism Spectrum Disorder. Am J Psychiatry 174:576-585
Anderson, Afrouz A; Smith, Elizabeth; Chowdhry, Fatima A et al. (2017) Prefrontal Hemodynamics in Toddlers at Rest: A Pilot Study of Developmental Variability. Front Neurosci 11:300
Ory, Daniel S; Ottinger, Elizabeth A; Farhat, Nicole Yanjanin et al. (2017) Intrathecal 2-hydroxypropyl-?-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet 390:1758-1768

Showing the most recent 10 out of 15 publications